Related references
Note: Only part of the references are listed.Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss
S. Jacob et al.
DIABETES OBESITY & METABOLISM (2009)
Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis: A Randomized, Prospective Trial
Stephen A. Harrison et al.
HEPATOLOGY (2009)
An RCT of metformin versus orlistat for the management of obese anovulatory women
M. Metwally et al.
HUMAN REPRODUCTION (2009)
Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study
Vijay Nambi et al.
STROKE (2009)
Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Matthias Briel et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Triglycerides and Risk for Coronary Artery Disease
Patrick McBride
CURRENT ATHEROSCLEROSIS REPORTS (2008)
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia
E. S. Nakou et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome
T. D. Filippatos et al.
DIABETES OBESITY & METABOLISM (2008)
Orlistat-associated adverse effects and drug interactions - A critical review
Theodosios D. Filippatos et al.
DRUG SAFETY (2008)
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia
E. S. Nakou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels (Reprinted from Heart, vol 94, pg 706-14, 2008)
D. J. Hausenloy et al.
POSTGRADUATE MEDICAL JOURNAL (2008)
Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance
A. N. Dixon et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome
Theodosios D. Filippatos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2008)
Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in healthy obese women
T. Tzotzas et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
D. J. Hausenloy et al.
HEART (2008)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome
T. D. Filippatos et al.
ATHEROSCLEROSIS (2007)
Orlistat increases serum paraoxonase activity in obese patients
Maria Audikovszky et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2007)
Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome
T. D. Filippatos et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2007)
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus
Kohzo Takebayashi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome
Themistoklis Tzotzas et al.
ANGIOLOGY (2007)
Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients - A 3-year randomized, placebo-controlled study
Bjorn Richelsen et al.
DIABETES CARE (2007)
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk - The Framingham Heart Study
Douglas S. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis
Nimer Assy et al.
GUT (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Antiatherogenic small, dense HDL - guardian angel of the arterial wall?
A Kontush et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2006)
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
K Al Majali et al.
DIABETOLOGIA (2006)
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma
I Gazi et al.
CLINICAL CHEMISTRY (2005)
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study
TD Filippatos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Serum γ-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors
DJ Kim et al.
DIABETIC MEDICINE (2005)
Effect of Orlistat on Plasma Leptin Levels and Risk Factors for the Metabolic Syndrome
Dimiter Dimitrov et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2005)
Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke - The Rotterdam Study
HHS Oei et al.
CIRCULATION (2005)
The effects of orlistat on metabolic parameters and other cardiovascular risk factors
DN Kiortsis et al.
DIABETES & METABOLISM (2005)
Pathogenesis and treatment of kidney disease and hypertension - Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
VG Athyros et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2004)
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
CM Ballantyne et al.
CIRCULATION (2004)
XENical in the prevention of diabetes in obese subjects (XENDOS) study
JS Torgerson et al.
DIABETES CARE (2004)
Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population -: Results from the 14-year follow-up of a large cohort from southern Germany
W Koenig et al.
CIRCULATION (2004)
Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase - Implication for atherosclerosis
M Eisaf et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors
L Samuelsson et al.
DIABETES OBESITY & METABOLISM (2003)
Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients
A Halpern et al.
DIABETES OBESITY & METABOLISM (2003)
Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia
CP Lucas et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet
G Derosa et al.
CLINICAL THERAPEUTICS (2003)
The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese chinese subjects with or without type 2 diabetes
PCY Tong et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Administration of orlistat in a patient with familial hyperchylomicronemia
T Tzotzas et al.
ATHEROSCLEROSIS (2002)
Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus
KCB Tan et al.
DIABETIC MEDICINE (2002)
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension
G Bakris et al.
JOURNAL OF HYPERTENSION (2002)
The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial
M Hanefeld et al.
DIABETES OBESITY & METABOLISM (2002)
Effects of orlistat, simvastatin, and orlistat plus simvastatin in obese patients with hypercholesterolemia: A randomized, open-label trial
G Derosa et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2002)
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
JM Miles et al.
DIABETES CARE (2002)
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes - A 1-year randomized controlled trial
DE Kelley et al.
DIABETES CARE (2002)
Orlistat: its current status as an anti-obesity drug
A Ballinger et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB
V Tsimihodimos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects
AM Rosenfalck et al.
DIABETES OBESITY & METABOLISM (2002)
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity
A Gokcel et al.
DIABETES OBESITY & METABOLISM (2002)
The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study
E Muls et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program
A Sartorio et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2001)
Orlistat inhibits dietary cholesterol absorption
B Mittendorfer et al.
OBESITY RESEARCH (2001)
Effect of orlistat-assisted weight rose in decreasing coronary heart disease risk in patients with syndrome X
G Reaven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Effects of short-term energy restriction and physical training on haemostatic risk factors for coronary heart disease in obese children and adolescents
S Gallistl et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Weight change and blood coagulability and fibrinolysis in healthy obese women
P Rissanen et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
High density lipoproteins and arteriosclerosis - Role of cholesterol efflux and reverse cholesterol transport
A von Eckardstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
CJ Packard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
SB Heymsfield et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Orlistat in the long-term treatment of obesity in primary care settings
J Hauptman et al.
ARCHIVES OF FAMILY MEDICINE (2000)
Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity
S Rossner et al.
OBESITY RESEARCH (2000)
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
F Lindgarde
JOURNAL OF INTERNAL MEDICINE (2000)
Share Paper
